Supriya Lifescience Aims To Double Revenue To Rs 1,000 Crore By FY27 — Know Your Company

The company plans for Rs 100 crore capex for the next two years. Of this, Rs 60-70 crore will be for their Lote Parshuram facility in Ratnagiri, where it is putting a new production block with a capacity of 300 KL. This will take the total capacity to 900 KL. CDMO/CMO, opportunities in API and advanced intermediates will be scaled up via this facility, Saloni said.

Supriya Lifescience expects tremendous growth in the existing portfolio as they have done filings in the regulated market.

The company is also entering into a new segment of dosage filings, for which it is building a facility in Ambernath. It is planning to spend Rs 60 crore for the facility over the next two years.

It plans to manufacture a new anesthetic product in the facility, in an effort to expand within the segment. The global market for the product is currently about $300 million and is growing at 4.5% CAGR for the next 10 years, Saloni said.

Currently, there is a dependence on China for this product globally, and this would be an import substitute product.

The company is targeting 20% market share in the next 2-3 years for the anesthetic product. It will set up a bottling line in Ambernath for it, with a capacity of five million bottles a year. The facility will be ready by August this year and will start contributing to top line from FY26, she said.

The company also has four new products in the pipeline for launch in fiscal 2025. These are from the anti-diabetic, anti-anxiety, and anesthetic categories.